...
首页> 外文期刊>Public health reports >Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015
【24h】

Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015

机译:医疗补助在美国,美国,2015年幼儿注意缺陷/多动障碍的药物治疗药物治疗授权政策

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objectives: In 2011, the American Academy of Pediatrics updated its guidelines for the diagnosis and treatment of children with attention-deficit/hyperactivity disorder (ADHD) to recommend that clinicians refer parents of preschoolers (aged 4-5) for training in behavior therapy and subsequently treat with medication if behavior therapy fails to sufficiently improve functioning. Data available from just before the release of the guidelines suggest that fewer than half of preschoolers with ADHD received behavior therapy and about half received medication. About half of those who received medication also received behavior therapy. Prior authorization policies for ADHD medication may guide physicians toward recommended behavior therapy. Characterizing existing prior authorization policies is an important step toward evaluating the impact of these policies on treatment patterns. We inventoried existing prior authorization policies and characterized policy components to inform future evaluation efforts.
机译:目标:2011年,美国儿科学会(American Academy of Pediatrics)更新了《注意缺陷多动障碍(ADHD)儿童诊断和治疗指南》,建议临床医生推荐学龄前儿童(4-5岁)的父母接受行为治疗培训,如果行为治疗未能充分改善功能,则随后进行药物治疗。指南发布前的数据表明,不到一半的多动症学龄前儿童接受了行为治疗,大约一半接受了药物治疗。大约一半接受药物治疗的人也接受了行为疗法。ADHD药物的事先授权政策可能会指导医生进行推荐的行为疗法。描述现有的事先授权政策是评估这些政策对治疗模式影响的重要一步。我们对现有的事先授权策略进行了清点,并对策略组件进行了描述,以便为未来的评估工作提供信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号